drugset / Trial / NCT05230810
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
NaSingle-groupOpen-labelTreatment
Summary
Phase IB/II clinical trial of Alpelisb and Tucatinib in patients with PIK3CA-Mutant HER2-positive metastatic breast cancer.
Timeline
- Start
- 2022-08-25
- Primary completion
- 2026-03-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alpelisib | Small molecule | 250 mg | Oral |
| Subject | Tucatinib | Small molecule | 300 mg | Oral |
| Background | Fulvestrant | Small molecule | 500 mg | Intramuscular |